Plasma amyloid‐beta42/40 ratio as biomarker of cerebral amyloidosis in cognitively unimpaired APOE‐e4 homozygotes, heterozygotes and non‐carriers

Authors :: Hillary Protas
Helen Hu
Willemijn J. Jansen
Ji Luo
Yinghua Chen
Connie A. Boker
Tim West
Yi Su
Valentina Ghisays
Philip B. Verghese
Kris Kirmess
Kevin E. Yarasheski
Kewei Chen
Eric M. Reiman
Kathryn L. DeMarco
Matthew R. Meyer
Source :: Alzheimer's & Dementia. 16
Publication Year :: 2020
Publisher :: Wiley, 2020.

Subjects :: Pathology
medicine.medical_specialty
Amyloid
Epidemiology
business.industry
Health Policy
Amyloidosis
Heterozygote advantage
medicine.disease
Psychiatry and Mental health
Cellular and Molecular Neuroscience
Developmental Neuroscience
medicine
Biomarker (medicine)
Neurology (clinical)
Geriatrics and Gerontology
business

Full Text Access

Tools